Starbucks: Analysts Expect Q4 Earnings of $0.99 Per Share

Starbucks (NASDAQ: SBUX) will be reporting its fourth quarter financial results today after the markets close. Analysts have a consensus $129.25 12-month price target on the company, via a total of 37 analysts, with 12 analysts having strong buy ratings. 10 analysts meanwhile have buy ratings, 14 analysts have a hold rating and a single analyst has a sell rating on the company. The street high comes from Kalinowski Equity Research with a $148 price target, and the lowest target sits at $95.

26 analysts have revenue estimates for the fourth quarter. The mean revenue estimate between all 26 analysts is $8.21 billion; this number has been revised upwards from $8.07 billion at the start of April. The highest revenue estimate is $8.45 billion, while the lowest is $7.92 billion.

Onto EBITDA estimates, there are currently 18 analysts who have fourth-quarter EBITDA estimates. The mean is currently $1.93 billion, with this number having been revised upwards from $1.9 billion at the start of April. The street high estimate currently sits at $2.05 billion in EBITDA and the lowest is $1.85 billion.

Analysts estimate that quarterly earnings per share will come in at $0.99, with this number being revised upwards from $0.96 at the start of April. Street high is $1.05 and the lowest estimate is $10.93 per share for the quarter.


Information for this briefing was found via Edgar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The $30,000 Gold Case Just Got Stronger | Simon Marcotte

Why Silver’s Move Is ‘Scary’ to Some Miners | Frank Basa

Are Commodities Entering a Generational Cycle? | Terry Lynch

Recommended

Ottawa Backs First Phosphate Battery Grade Validation Push With $16.7M Boost

First Majestic Drills 3.43 g/t Gold Over 24.4 Metres At Jerritt Canyon

Related News

Vireo Health: Canaccord Reiterates After Q4 Results

Last week, Vireo Health (CSE: VREO) released their fourth quarter and year-end 2020 financial results....

Monday, March 29, 2021, 04:03:00 PM

MicroStrategy: Canaccord Lowers Price Target To $780

MicroStrategy (NASDAQ: MSTR) reported its second quarter financial results on July 29. The company reported...

Tuesday, August 3, 2021, 11:35:00 AM

Mindmed: Eight Capital Resumes Coverage With $6.50 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes...

Friday, September 17, 2021, 03:23:00 PM

Canopy Growth: Analysts Raise Price Targets Following Q2 Results

On Monday, Canopy Growth (TSX: WEED) (NYSE: CGC) reported its fiscal second quarter 2021 financial...

Thursday, November 12, 2020, 01:17:00 PM

Peloton: Analysts Expect $1.11 Billion In Revenue For Q3

Peloton Interactive (NASDAQ: PTON) will be reporting its fiscal third quarter financial results today after...

Thursday, May 6, 2021, 11:06:00 AM